Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Clinical Trials as Topic
  • Endpoint Determination
  • Prostatic Neoplasms
  • Research Design
  • Testosterone

abstract

  • PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.

publication date

  • March 2008

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4010133

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.12.4487

PubMed ID

  • 18309951

Additional Document Info

start page

  • 1148

end page

  • 59

volume

  • 26

number

  • 7